GH Research PLC

NASDAQ:GHRS

Biotechnology

Healthcare
$18.25 -0.18%

-$0.04 today

Market cap
$1.25B
Beta
1.31
P/E (TTM)
-23.8
EPS (TTM)
-$0.91
52W Low $11.32High $25.94

Volume 0.46M

Average 0.23M

GHRS Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

GH Research PLCNASDAQ: GHRS

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow growth accelerates

Q1 FY2026 free cash flow of $10.73M (cash outflow) rose 25.1% year over year, ahead of the +12.6% change in trailing-twelve-month free cash flow. Sequentially, it fell 12.6% from the prior quarter. Over 3 fiscal years it compounded at +18.5% a year.

Context

  • Free cash flow grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +25.1% holds above the trailing-twelve-month pace of +12.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$10.73M-12.6% QoQ
Last fiscal yearDec 2025
-$43.67M+3.2% YoY
LTMMar 2026
-$46.51M+12.6% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+25.1%——
1 year+3.2%——
3-year CAGR+18.5%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(43.67M) USD
Year-over-year change
-3.2%

Free Cash Flow vs competitors

How GHRS compares with its peers on the latest reported figures

  • GHRS's LTM Mar 2026 free cash flow of $46.51M is the smallest of the 9 companies compared; the peer median is $177.27M.
  • Its year-over-year change of +12.6% is the 5th highest of 7, against a peer median of +15.7%.
  • Over three fiscal years its annual growth of +18.5% compares with a peer median of +54.9%.
GHRS Competitors Peer median
Free Cash Flow for GHRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NERVMinerva Neurosciences, Inc.LTM Jun 2026$18.78B —+718.3%—
BHVNBiohaven Ltd.LTM Jun 2026$511.87M -20.8%+21.7%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$193.4M -3.0%+21.4%—
DFTXDefinium Therapeutics, Inc.LTM Sep 2026$190.28M +67.0%+37.9%—
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$164.26M +92.8%+71.8%—
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$80.71M +16.8%+192.3%403.5%
ANROAlto Neuroscience, Inc.LTM Mar 2026$62.86M +14.6%+34.8%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$51.71M —+134.7%—
GHRSGH Research PLCLTM Mar 2026$46.51M +12.6%+18.5%—
SPTXSeaport Therapeutics, Inc. Common Stock—— ———
Peer median (excluding GHRS) $177.27M+15.7%+54.9%403.5%

Competitors are the stored peer set for GHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(9.2M)(22.46M)(35.59M)(38.96M)(48.26M)
Depreciation & Amortization19K47K315K315K335K
Deferred Income Tax(5.92M)0000
Stock-Based Compensation366K1.67M2.29M1.17M0
Change in Working Capital(559K)2.16M1.65M188K(3.09M)
Accounts Receivables00000
Inventory00000
Accounts Payables00000
Other Working Capital(559K)2.16M1.65M188K(3.09M)
Other Non-Cash Items9K(7.62M)(2M)(5M)7.46M
Operating Cash Flow(15.28M)(26.2M)(33.34M)(42.29M)(43.55M)
Capital Expenditures(104K)(67K)(100K)(49K)(121K)
Acquisitions (Net)00000
Purchases of Investments0(84.62M)(54M)00
Sales of Investments00065.18M46.29M
Other Investing Activities00000
Investing Cash Flow(104K)(84.69M)(54.1M)65.14M46.17M
Debt Repayment00(219K)(304K)0
Common Stock Issued309.2M015K0139.85M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(22.75M)000(197K)
Financing Cash Flow286.45M0(204K)(304K)139.65M
Effect of Forex Changes(179K)66K105K(175K)3.19M
Net Change in Cash270.88M(110.82M)(87.54M)22.37M145.46M
Free Cash Flow(15.39M)(26.27M)(33.44M)(42.33M)(43.67M)

GH Research PLC

NASDAQ:GHRS

Intrinsic Alpha fair value

Locked

Current Price

$18.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.